{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:07:10Z","timestamp":1780409230741,"version":"3.54.1"},"reference-count":28,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,2,1]]},"DOI":"10.1210\/jc.2006-1587","type":"journal-article","created":{"date-parts":[[2006,11,14]],"date-time":"2006-11-14T23:14:39Z","timestamp":1163546079000},"page":"476-482","source":"Crossref","is-referenced-by-count":80,"title":["Treatment with Growth Hormone Receptor Antagonist in Acromegaly: Effect on Cardiac Structure and Performance"],"prefix":"10.1210","volume":"92","author":[{"given":"Rosario","family":"Pivonello","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (R.P., R.S.A., M.C.D.M., M.Galdi., A.Ci., G.L., A.Co.), \u201cFederico II\u201d University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Galderisi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine (M.Galde., A.D.), \u201cFederico II\u201d University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata S.","family":"Auriemma","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (R.P., R.S.A., M.C.D.M., M.Galdi., A.Ci., G.L., A.Co.), \u201cFederico II\u201d University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"De Martino","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (R.P., R.S.A., M.C.D.M., M.Galdi., A.Ci., G.L., A.Co.), \u201cFederico II\u201d University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Galdiero","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (R.P., R.S.A., M.C.D.M., M.Galdi., A.Ci., G.L., A.Co.), \u201cFederico II\u201d University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ciccarelli","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (R.P., R.S.A., M.C.D.M., M.Galdi., A.Ci., G.L., A.Co.), \u201cFederico II\u201d University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangelo","family":"D\u2019Errico","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine (M.Galde., A.D.), \u201cFederico II\u201d University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ione","family":"Kourides","sequence":"additional","affiliation":[{"name":"Department of Pfizer Inc. (I.K., P.B.), New York, New York 10017"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Burman","sequence":"additional","affiliation":[{"name":"Department of Pfizer Inc. (I.K., P.B.), New York, New York 10017"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (R.P., R.S.A., M.C.D.M., M.Galdi., A.Ci., G.L., A.Co.), \u201cFederico II\u201d University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (R.P., R.S.A., M.C.D.M., M.Galdi., A.Ci., G.L., A.Co.), \u201cFederico II\u201d University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2006,11,14]]},"reference":[{"key":"key\n\t\t\t\t2019041113395451700_R1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management.","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041113395451700_R2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1210\/er.2003-0009","article-title":"Cardiovascular function in acromegaly.","volume":"24","author":"Clayton","year":"2003","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041113395451700_R3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1056\/NEJM199004053221405","article-title":"Acromegaly.","volume":"322","author":"Melmed","year":"1990","journal-title":"N Engl J Med"},{"issue":"Suppl 8","key":"key\n\t\t\t\t2019041113395451700_R4","first-page":"39","article-title":"The treatment algorithm of acromegaly","volume":"26","author":"Colao","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113395451700_R5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/er.2001-0022","article-title":"Growth hormone receptor antagonist: discovery, development and use in patients with acromegaly.","volume":"23","author":"Kopchick","year":"2002","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041113395451700_R6","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long term treatment of acromegaly with pegvisomant, a growth hormone antagonist.","volume":"358","author":"Lely","year":"2001","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113395451700_R7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-months of treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.","volume":"154","author":"Colao","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113395451700_R8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0002-9149(97)89313-7","article-title":"Impact of ambulatory blood pressure on left ventricular diastolic dysfunction in uncomplicared arterial hypertension.","volume":"77","author":"Galderisi","year":"1996","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041113395451700_R9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/01.CIR.55.4.613","article-title":"Echocardiographic determination of left ventricular mass: anatomic validation of the method.","volume":"55","author":"Devereux","year":"1977","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041113395451700_R10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2265.2001.01218.x","article-title":"Growth hormone and the heart.","volume":"54","author":"Colao","year":"2001","journal-title":"Clin Endocrinol"},{"key":"key\n\t\t\t\t2019041113395451700_R11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/s-2007-978698","article-title":"The role of the GH\/IGF-I axis for the cardiac function and structure.","volume":"31","author":"Isgaard","year":"1999","journal-title":"Horm Metab Res"},{"key":"key\n\t\t\t\t2019041113395451700_R12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1677\/joe.0.1200107","article-title":"Growth hormone regulates the level of insulin-like growth factor-I mRNA in rats skeletal muscle.","volume":"120","author":"Isgaard","year":"1989","journal-title":"J Endocrinol"},{"key":"key\n\t\t\t\t2019041113395451700_R13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0008-6363(95)00163-8","article-title":"Insulin-like growth factor I and its binding proteins in the cardiovascular system.","volume":"30","author":"Delafontaine","year":"1995","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t2019041113395451700_R14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1126\/science.3563497","article-title":"Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus.","volume":"236","author":"Han","year":"1987","journal-title":"Science"},{"key":"key\n\t\t\t\t2019041113395451700_R15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1161\/01.CIR.93.4.800","article-title":"Differential cardiac effects of growth hormone and insulin-like growth factor-I in the rat. A combined in vivo and in vitro evaluation.","volume":"93","author":"Cittadini","year":"1996","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041113395451700_R16","doi-asserted-by":"crossref","first-page":"22892","DOI":"10.1074\/jbc.M011647200","article-title":"Demonstration of direct effects of growth hormone on neonatal cardiomyocytes.","volume":"276","author":"Lu","year":"2001","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t2019041113395451700_R17","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/BF01906959","article-title":"Insulin-like growth factors and insulin increase the contractility of neonatal rat cardiocytes in vitro.","volume":"83","author":"Vetter","year":"1988","journal-title":"Basic Res Cardiol"},{"key":"key\n\t\t\t\t2019041113395451700_R18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1020750514954","article-title":"Cardiovascular complications in acromegaly: methods of assessment.","volume":"4","author":"Vitale","year":"2001","journal-title":"Pituitary"},{"key":"key\n\t\t\t\t2019041113395451700_R19","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.7326\/0003-4819-34-6-1445","article-title":"Acromegaly and the heart: a clinical and pathologic study.","volume":"34","author":"Hejtmancik","year":"1951","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041113395451700_R20","first-page":"193","article-title":"Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113395451700_R21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2265.2001.01218.x","article-title":"Growth hormone and the heart.","volume":"54","author":"Colao","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113395451700_R22","first-page":"3132","article-title":"Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113395451700_R23","first-page":"527","article-title":"Cardiac effects of lanreotide, a slow release somatostatin analog in acromegalic patients.","volume":"84","author":"Baldelli","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113395451700_R24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/jcem.84.1.5368","article-title":"Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly.","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113395451700_R25","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1007\/BF03349164","article-title":"Diagnosis and treatment of acromegaly complications.","volume":"26","author":"Giustina","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113395451700_R26","first-page":"1551","article-title":"Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance.","volume":"86","author":"Colao","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113395451700_R27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2265.2003.01689.x","article-title":"Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue Octreotide.","volume":"58","author":"Colao","year":"2003","journal-title":"Clin Endocrinol"},{"key":"key\n\t\t\t\t2019041113395451700_R28","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.","volume":"90","author":"Barkan","year":"2005","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/2\/476\/9051106\/jcem0476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T06:08:18Z","timestamp":1555913298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/2\/476\/2566775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,14]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2006,11,14]]},"published-print":{"date-parts":[[2007,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2006-1587","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,14]]}}}